UK report: State of the Discovery Nation 2018

18 January 2018

A joint report by the UK’s BioIndustry Association (BIA) and the Medicines Discovery Catapult (MDC), a government-backed innovation center, based on surveys and over 100 in-depth interviews with senior executives of UK drug discovery companies, shows that global R&D productivity is under unprecedented pressure.

With the financial burden of disease rising faster than Gross Domestic Product (GDP) due to an aging population and the rise of chronic diseases, there is an urgent need for more cost-effective medicine development, the report notes. Despite this, around 40% of new drugs fail when they are first trialled in a patientand the majority fail at other stages of development. As a result, the number of drugs launched per $1billion of R&D spend has fallen nearly thirtyfold over the last 40 years.

In response to this, world leading opportunities exist for the UK to reshape the medicines discovery process to develop medicines greatly needed by patients. The report highlights that:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK